Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2025-12-24 @ 5:33 PM
NCT ID:
NCT01843868
Eligibility Criteria:
Inclusion Criteria:
1. Histologically confirmed diagnosis of non Hodgkin's Lymphoma
2. Newly diagnosed or relapsed patients who are chemotherapy-naïve or who have not received chemotherapy in the last 12 months. Pre-phase therapy with prednisolone and/or vincristine for \< one week duration prior to commencement of cycle 1 of R-CHOP is permissible
3. Intended to receive R-CHOP every 14 or 21 days for minimum 3 cycles with rituximab planned to be given with CHOP on day 1 or fractionated over days 1 and 21.
4. Males and females, age 18 years or older
5. Are reasonably expected to be able to complete the CINV tool
6. Willing to complete assessments and tool as required for the study
7. ECOG (Eastern Cooperative Oncology Group) performance status score of 2 or less
8. Has provided written informed consent
Exclusion Criteria:
1. Women who are pregnant or lactating.
2. Previous adverse reaction to the standard anti-emetics proposed in the study
3. Contraindications to the use of the anti-emetics included as standard of care in the study (e.g. cardiac, liver function)
4. Participation in other therapeutic studies investigating CINV.
5. Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study
6. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01843868
Study Brief:
Protocol Section:
NCT01843868